Neutrophil‐to‐lymphocyte ratio and the systemic immune‐inflammation index as potential biomarkers of effective treatment and subclinical atherosclerotic cardiovascular disease in patients with psoriasis.

However, markers of systemic inflammation were numerically lower in patients treated with biologics and these biologics may hold the potential to reduce the risk of CVD in patients with psoriasis. The mean SII (492.7 ± 363.0 vs. 696.2 ± 246.3 [ I p i = 0.017]) and NLR (1.95 ± 1.11 vs. 2.77 ± 0.86 [ I p i = 0.002]) were lower in the patients receiving biologic treatment compared to the untreated patients. Psoriasis is a systemic inflammatory disease that is associated with a disease severity-dependent increased risk of atherosclerotic cardiovascular disease (CVD).[1] Increased burden of systemic inflammation and traditional cardiovascular risk factors are thought to increase the risk of CVD in psoriasis, and shared inflammatory pathways represent a possible link between the two diseases.[1] Biomarkers of systemic inflammation such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and high-sensitivity C-reactive protein (hs-CRP) are increased in patients with psoriasis compared to healthy controls.[[2]] Furthermore, increased NLR is associated with CVD in patients with psoriasis.[[4]] Recently, the systemic immune-inflammation index (SII), which is calculated by the following formula: neutrophils × platelets/lymphocytes and thus combines NLR and PLR in one index, was also shown to be increased in patients with psoriasis.[[6]] It is unknown which biomarker of systemic inflammation best captures both disease activity measured by psoriasis area and severity index (PASI)[[2], [8]] and risk of CVD in patients with psoriasis. [Extracted from the article]